Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-07-22 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L 3 pages 202.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the FDA has accepted Mesoblast's Biologics License Application (BLA) resubmission for Ryoncil, a cellular medicine for children with steroid-refractory acute graft-versus-host disease. It provides detailed information about the product, clinical trial results, regulatory status, and forward-looking statements. There are no financial statements, quarterly or annual report data, or detailed management discussion of financial results. The document is not a regulatory filing or certification but a corporate announcement about a regulatory milestone and product development progress. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is best classified as a Regulatory Filings (RNS) type, which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length and content confirm it is not a brief announcement but a detailed regulatory update press release.
2024-07-22 English
Confirmatory Phase 3 Back Pain Trial Actively Enrols 2 pages 164.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the commencement of patient enrollment in a pivotal Phase 3 clinical trial for a product called rexlemestrocel-L. It provides detailed information about the trial design, FDA designations, and the company's background. There are no financial statements, regulatory filings, or detailed financial performance data. The document is not an earnings release, annual report, or interim report. It is a corporate announcement related to clinical trial progress and product development, which does not fit into the specific financial or regulatory filing categories. It is not a report publication announcement since it does not mention the release of a report. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2024-07-21 English
Change in substantial holding 4 pages 212.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in substantial shareholdings, voting power, and relevant interests of a substantial holder in Mesoblast Limited. The form includes dates of changes, nature of changes, and number of securities affected. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report, but a regulatory notice about shareholding changes.
2024-07-11 English
Notification of cessation of securities - MSB 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (lapse) of certain securities (options) for Mesoblast Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a regulatory announcement related to changes in the company's issued securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or other report content. The document length is 3872 characters, which is relatively short and focused on a specific securities cessation event. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities changes that does not fit into more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS), since it is about cessation of securities rather than issuance or buyback. Therefore, the best classification is Regulatory Filings (RNS).
2024-07-11 English
Notification regarding unquoted securities - MSB 6 pages 19.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme by Mesoblast Limited. It includes specifics such as security codes, issue dates, numbers of securities issued, and mentions key management personnel involved. The document is a formal notification of securities issuance rather than a financial report or earnings release. It aligns with announcements related to share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is 5703 characters, sufficient to contain substantive details of the issuance rather than a brief announcement or a report publication notice.
2024-07-11 English
Appendix 3Y for Philip Krause 2 pages 222.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change, and dates. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3566 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is Director's Dealing (DIRS).
2024-07-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.